Hypolipidemic treatment of heterozygous familial hypercholesterolemia: a lifelong challenge
| Autor: | Petri T. Kovanen, Alpo F Vuorio, Helena Gylling |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
medicine.medical_specialty
Heterozygote Statin Combination therapy medicine.drug_class Familial hypercholesterolemia Gastroenterology Hyperlipoproteinemia Type II Ezetimibe Internal medicine Internal Medicine medicine Humans Hypolipidemic Agents business.industry General Medicine Statin treatment medicine.disease Young age Endocrinology Receptors LDL LDL receptor Mutation lipids (amino acids peptides and proteins) Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business medicine.drug Lipoprotein |
| Zdroj: | Expert review of cardiovascular therapy. 2(3) |
| ISSN: | 1477-9072 |
| Popis: | In familial hypercholesterolemia, a defect in low-density lipoprotein receptors causes lifelong two- to threefold elevations in serum low-density lipoprotein-cholesterol levels. This leads to early atherosclerotic changes in infancy. Lifelong hypolipidemic treatment that can be started at a young age is thus greatly needed. Early diagnosis of familial hypercholesterolemia is important, and improved DNA tests for low-density lipoprotein receptor mutations have made it possible to carry out diagnosis at birth. A low saturated-fat, low cholesterol diet can be safely started at 7 months of age. This can be accompanied by dietary stanol esters from 2 years of age. At the age of 10, statin treatment can be safely started. In adults, more aggressive hypolipidemic treatment is required in order to reach the treatment goal for serum low-density lipoprotein-cholesterol levels less than 2.5 mmol/l. This can be achieved by using high doses of statin, or preferably by combining a statin with resin or ezetimibe (Zeita), Merck and Shering-Plough Pharmaceuticals). Once started, treatment of familial hypercholesterolemia is lifelong. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|